International Journal of Nanomedicine (May 2023)

Therapeutic Potential of Nanomedicine in Management of Alzheimer’s Disease and Glioma

  • Anwar F,
  • Al-Abbasi FA,
  • Naqvi S,
  • Sheikh RA,
  • Alhayyani S,
  • Asseri AH,
  • Asar TO,
  • Kumar V

Journal volume & issue
Vol. Volume 18
pp. 2737 – 2756

Abstract

Read online

Firoz Anwar,1 Fahad A Al-Abbasi,1 Salma Naqvi,2 Ryan Adnan Sheikh,1 Sultan Alhayyani,3 Amer H Asseri,1 Turky Omar Asar,1 Vikas Kumar4 1Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia; 2Department of Biomedical Sciences, College of Medicine, Gulf Medical University, Ajman, United Arab Emirates; 3Department of Chemistry, College of Sciences & Arts, Rabigh King Abdulaziz University, Jeddah, Saudi Arabia; 4Natural Product Discovery Laboratory, Department of Pharmaceutical Sciences, Shalom Institute of Health and Allied Sciences, SHUATS, Prayagraj, IndiaCorrespondence: Firoz Anwar; Vikas Kumar, Email [email protected]; [email protected]: Neoplasm (Glioblastoma) and Alzheimer’s disease (AD) comprise two of the most chronic psychological ailments. Glioblastoma is one of the aggressive and prevalent malignant diseases characterized by rapid growth and invasion resulting from cell migration and degradation of extracellular matrix. While the latter is characterized by extracellular plaques of amyloid and intracellular tangles of tau proteins. Both possess a high degree of resistance to treatment owing to the restricted transport of corresponding drugs to the brain protected by the blood–brain barrier (BBB). Development of optimized therapies using advanced technologies is a great need of today. One such approach is the designing of nanoparticles (NPs) to facilitate the drug delivery at the target site. The present article elaborates the advances in nanomedicines in treatment of both AD as well as Gliomas. The intention of this review is to provide an overview of different types of NPs with their physical properties emphasizing their importance in traversing the BBB and hitting the target site. Further, we discuss the therapeutic applications of these NPs along with their specific targets. Multiple overlapping factors with a common pathway in development of AD and Glioblastoma are discussed in details that will assist the readers in developing the conceptual approach to target the NP for an aging population in the given circumstances with limitations of currently designed NPs, and the challenges to meet and the future perspectives.Keywords: therapeutic potential, Alzheimer’s disease, glioma, nanomedicine, blood–brain barrier

Keywords